Mycophenolate Mofetil · Regulatory label update

FDA supplemental approval: Mycophenolate Mofetil (REMS)

U.S. Food and Drug Administration · July 29, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

This is an FDA regulatory action approving a Risk Evaluation and Mitigation Strategy (REMS) supplement for mycophenolate mofetil 250 mg capsules by Alkem Labs Ltd. The record documents the approval date and product specifications but contains no clinical efficacy, safety, or trial data.

What was studied

Regulatory label update.

Key findings

Supplemental REMS approval granted for mycophenolate mofetil 250 mg capsule, oral formulation Approval status date: 29 July 2026 Sponsor: Alkem Labs Ltd

Safety

This regulatory record documents approval action only and does not contain clinical trial results, efficacy data, or comparative safety information.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

FDA supplemental approval for mycophenolate mofetil REMS; this is a regulatory action, not a clinical evidence assessment.

Reported figures

Quoted from the source exactly as published.

Approval status date2026-07-29

Dose approved250 mg

Caveats

This regulatory record documents approval action only and does not contain clinical trial results, efficacy data, or comparative safety information.
No information on REMS requirements, indication, or clinical population affected.
No outcome, event rate, or risk data reported.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory action; no clinical study design reported.

Directness

insufficient

Record documents approval status only; no clinical outcome data.

Consistency

insufficient

Single regulatory submission; no comparative or replication data.

Risk of bias

insufficient

Regulatory record; bias assessment not applicable.

Sample adequacy

insufficient

No patient population or sample size data reported.

Source abstract

Drugs@FDA record for application ANDA200197. This is a regulatory action record, not a clinical study. Brand name: MYCOPHENOLATE MOFETIL. Active ingredient: MYCOPHENOLATE MOFETIL. Sponsor: ALKEM LABS LTD. Submission type: SUPPL (supplement). Submission class: REMS. Approval status date: 2026-07-29. Products: MYCOPHENOLATE MOFETIL, CAPSULE, ORAL, MYCOPHENOLATE MOFETIL 250MG.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Mycophenolate MofetilAlkem Labs